Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults.
| Title | Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults. |
| Publication Type | Journal Article |
| Year of Publication | 2016 |
| Authors | Rapti, E., Karras S., Grammatiki M., Mousiolis A., Tsekmekidou X., Potolidis E., Zebekakis P., Daniilidis M., & Kotsa K. |
| Journal | Endocrinol Diabetes Metab Case Rep |
| Volume | 2016 |
| Pagination | 150136 |
| Date Published | 2016 |
| ISSN | 2052-0573 |
| Abstract | UNLABELLED: Latent autoimmune diabetes in adults (LADA) is a relatively new type of diabetes with a clinical phenotype of type 2 diabetes (T2D) and an immunological milieu characterized by high titers of islet autoantibodies, resembling the immunological profile of type 1 diabetes (T1D). Herein, we report a case of a young male, diagnosed with LADA based on both clinical presentation and positive anti-glutamic acid decarboxylase antibodies (GAD-abs), which were normalized after combined treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4) (sitagliptin) and cholecalciferol.LEARNING POINTS: Anti-glutamic acid decarboxylase antibodies (GAD-abs) titers in young patients being previously diagnosed as type 2 diabetes (T2D) may help establish the diagnosis of latent autoimmune diabetes in adults (LADA).Sitagliptin administration in patients with LADA might prolong the insulin-free period.Vitamin D administration in patients with LADA might have a protective effect on the progression of the disease. |
| DOI | 10.1530/EDM-15-0136 |
| Alternate Journal | Endocrinol Diabetes Metab Case Rep |
| PubMed ID | 27252860 |
| PubMed Central ID | PMC4888610 |
